Cristina Saura

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer

  npj Breast Cancer · 2026-06-17

• Data from PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2− Breast Cancer: Clinical and Circulating Tumor DNA Results

  2026-06-17

• Supplementary Data1 from PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2− Breast Cancer: Clinical and Circulating Tumor DNA Results

  2026-06-17

• European consensus on pre-operative imaging in breast cancer developed jointly by EUSOBI, ESSO, ESP and ESTRO

  European Radiology · 2026-06-16

• Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial

  European Journal of Cancer · 2026-06-12

• Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results

  npj Breast Cancer · 2026-05-29

• ReDiscover-2, a phase 3 study of zovegalisib (zovega, RLY-2608) + fulvestrant (fulv) versus capivasertib (capi) + fulv as treatment for locally advanced or metastatic <i>PIK3CA</i> -mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

  Journal of Clinical Oncology · 2026-05-28

• Quality and safety of research biopsies in oncology clinical trials

  European Journal of Cancer · 2026-05-25

• Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial

  UNC Libraries · 2026-05-07

• Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial

  Annals of Oncology · 2026-05-01

• Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial

  npj Breast Cancer · 2026-04-27

• Abstract LB413: Peripheral blood as the sole source for cancer neoantigen and reactive T cell discovery

  Cancer Research · 2026-04-17

• Evolving landscape of targeted therapies in early phase clinical trials

  European Journal of Cancer · 2026-04-12

• Supplementary Figure S6 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with &lt;i&gt;PIK3CA&lt;/i&gt;-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S13 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with &lt;i&gt;PIK3CA&lt;/i&gt;-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Table S1 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with &lt;i&gt;PIK3CA&lt;/i&gt;-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Table S4 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with &lt;i&gt;PIK3CA&lt;/i&gt;-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S10 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with &lt;i&gt;PIK3CA&lt;/i&gt;-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S3 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with &lt;i&gt;PIK3CA&lt;/i&gt;-Mutated Solid Tumors and in Preclinical Models

  2026-01-06

• Supplementary Figure S7 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with &lt;i&gt;PIK3CA&lt;/i&gt;-Mutated Solid Tumors and in Preclinical Models

  2026-01-06